Combination Chemotherapy Principles
Combining drugs with different mechanisms, non-overlapping toxicities, and independent resistance pathways maximizes tumor kill while preserving patient tolerance.
## Overview
Most curative chemotherapy regimens use multiple drugs in combination. The rationale is rooted in tumor heterogeneity and resistance: combining agents with different mechanisms of action kills cells that might be resistant to any individual drug, while different toxicity profiles allow each drug to be used at full doses.
## Principles of Drug Combination
1. **Each drug should be active as a single agent**: Combining ineffective drugs does not improve outcomes.
2. **Non-overlapping toxicities**: Allows full dosing of each drug without additive dose-limiting toxicity. Example: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) — myelosuppression (doxorubicin, dacarbazine), pulmonary (bleomycin), neuropathy (vinblastine).
3. **Different mechanisms of action**: Attacks multiple tumor cell vulnerabilities simultaneously.
4. **Non-cross-resistant mechanisms**: Prevents pre-existing resistance from rendering the entire combination ineffective.
5. **Optimal scheduling**: Some combinations require specific sequencing (e.g., fluorouracil before leucovorin to maximize TS binding).
## Landmark Combination Regimens
**MOPP/ABVD** (Hodgkin lymphoma): Established that curative intent was achievable with combination therapy. ABVD is now standard due to lower leukemia risk.
**CHOP + R** (NHL): Cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab. Addition of rituximab (R-CHOP) dramatically improved survival in DLBCL.
**FOLFOX/FOLFIRI** (colorectal cancer): Folate, fluorouracil + oxaliplatin or irinotecan. Backbone of first-line colorectal cancer therapy.
**BEP** (testicular cancer): Bleomycin, etoposide, cisplatin — one of the most curative regimens in oncology.
## Dose Intensity and Norton-Simon Model
The Norton-Simon model suggests that tumor growth follows Gompertzian kinetics; rapidly reducing tumor bulk early is most effective. Dose-dense regimens (e.g., dose-dense AC→T in breast cancer) deliver cycles every 2 weeks with G-CSF support instead of every 3 weeks, improving outcomes.
## Sequencing Targeted + Cytotoxic Therapy
Concurrent targeted therapy with chemotherapy does not always improve outcomes and can antagonize cytotoxic effects. Trastuzumab + taxane is synergistic; trastuzumab + lapatinib has additive HER2 blockade. EGFR TKIs + chemotherapy in EGFR-mutant NSCLC is not superior to sequential use.
## Key Takeaways
- Effective combination chemotherapy requires individually active agents with non-overlapping toxicities
- CHOP-R cures most DLBCL; BEP cures most testicular cancer — historic proof of combination principle
- Dose-dense scheduling with G-CSF support improves dose intensity without increased toxicity
- Targeted therapy + chemotherapy combinations require evidence of synergy; not all are beneficial